LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY - Concepedia

Concepedia

Publication | Open Access

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

DOI Full Paper Access

19

Citations

0

References

2022

Year

E. Morand, Margaret N. Pike, JT Merrill, Ronald van Vollenhoven, V. P. Werth, Coburn Hobar, Nikolay Delev, V. Shah, Brian J. Sharkey, T. Wegman,

Annals of the Rheumatic Diseases

No additional data available for this publication yet. Check back later!